As of July 2024, there are three FDA-approved bispecific antibody therapies available to treat multiple myeloma.
Several bispecific antibodies are in clinical trials and are expected to be approved within the next 2-3 years. This guide will be updated as more bispecific antibodies are approved.
The three currently approved therapies are:
Although commercially available, these therapies might also be received through a clinical trial, as they are being tested in a wider population and combined with other myeloma treatments (See Treatment Strategies with Bispecific Antibodies).